Show simple item record

dc.contributor.authorHallstensen, Randi
dc.contributor.authorBergseth, Grete
dc.contributor.authorFoss, Stian
dc.contributor.authorJæger, Steinar
dc.contributor.authorGedde-Dahl, Thobias
dc.contributor.authorHolt, jan
dc.contributor.authorChristiansen, Dorte
dc.contributor.authorLau, Corinna
dc.contributor.authorBrekke, Ole Lars
dc.contributor.authorArmstrong, Elina
dc.contributor.authorStefanovic, Vedran
dc.contributor.authorAndersen, Jan Terje
dc.contributor.authorSandlie, Inger
dc.contributor.authorMollnes, Tom Eirik
dc.date.accessioned2016-02-26T12:45:20Z
dc.date.accessioned2016-04-04T13:45:04Z
dc.date.available2016-02-26T12:45:20Z
dc.date.available2016-04-04T13:45:04Z
dc.date.issued2015
dc.identifier.citationImmunobiology 2015, 220(4):452-459nb_NO
dc.identifier.issn0171-2985
dc.identifier.urihttp://hdl.handle.net/11250/2383821
dc.description.abstractEculizumab is a humanized IgG2/4 chimeric anti-complement C5 antibody used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome. The aim of this study was to evaluate whether or not the complement activity in newborns from pregnant women who receive eculizumab is impaired. A novel eculizumab-C5 complex (E-C5) specific assay was developed and revealed that two newborns carried only 6–7% of the E-C5 detected in their eculizumab-treated PNH mothers. Serum from the pregnant women completely lacked terminal complement pathway activity, whereas the complement activity in the serum of the newborns was completely normal. Data from the pregnant women and their newborns were compared with that of healthy age-matched female controls and healthy newborns, as well as a non-treated pregnant woman with PNH and her newborn. These all showed normal complement activity without detectable E-C5 complexes. Furthermore, absence of eculizumab or E-C5 in the newborn could not be explained by lack of eculizumab binding to the neonatal Fc receptor (FcRn), as eculizumab bound strongly to the receptor in vitro. In conclusion, despite binding to FcRn neither eculizumab nor E-C5 accumulates in fetal plasma, and eculizumab treatment during pregnancy does not impair the complement function in the newborn.nb_NO
dc.language.isoengnb_NO
dc.publisherElseviernb_NO
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/
dc.titleEculizumab treatment during pregnancy does not affect the complement system activity of the newbornnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.date.updated2016-02-26T12:45:20Z
dc.source.pagenumber452-459nb_NO
dc.source.volume220nb_NO
dc.source.journalImmunobiologynb_NO
dc.source.issue4nb_NO
dc.identifier.doi10.1016/j.imbio.2014.11.003
dc.identifier.cristin1182182
dc.relation.projectNorges forskningsråd: 223255nb_NO
dc.description.localcodeAttribution-NonCommercial-NoDerivs 3.0 Unportednb_NO


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/3.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/3.0/